Company (location) |
Product |
Description |
Indication |
Status |
Date |
Achaogen Inc. (South San Francisco) |
Plazomicin |
Aminoglycoside antibiotic |
Complicated urinary tract infection, including acute pyelonephritis |
Phase III EPIC study comparing plazomicin to meropenem showed that plazomicin demonstrated a composite cure rate of 72% vs. 56.5% (difference [plazomicin minus meropenem]: 15.5, 95% CI: -13.7 to 41.9) |
6/6/17 |
Aridis Pharmaceuticals Inc. (San Jose, Calif.) |
Salvecin (AR-301) |
Human monoclonal antibody |
Severe pneumonia caused by Staphylococcus aureus |
Top-line phase IIa data showed no related serious adverse events at any dose level tested, and no difference in adverse effects was observed among the groups |
6/6/17 |
Matinas Biopharma Holdings Inc. (Bedminster, N.J.) |
MAT-2203 |
Encochleated formulation of amphotericin B |
Chronic refractory mucocutaneous candidiasis infection |
Interim data from the collaborative phase IIa study showed both patients met the primary endpoint, achieving ≥ 50% clinical response; MAT-2203 was well-tolerated |
6/6/17 |
Rebiotix Inc. (Roseville, Minn.) |
RBX-2660 |
Microbiota restoration therapy |
Clostridium difficile infections |
Two separate data analyses from the PUNCH CD2 trial demonstrated a single dose demonstrated a significantly better treatment response rate of preventing recurrent C. difficile infections than placebo (67% vs. 46%, respectively; p = 0.048) |
6/8/17 |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) |
TP-6076 |
Synthetic, fluorocycline antibiotic |
Serious and life-threatening bacterial infections |
Phase I data showed it was well-tolerated and there were no serious or severe adverse events, or discontinuations due to an adverse event |
6/6/17 |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) |
TP-271 |
Broad-spectrum antibiotic |
Respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens |
It was well-tolerated at single doses that resulted in high plasma exposures, with no clinically significant changes in lab values, ECG parameters or physical exam findings |
6/6/17 |
Theravance Biopharma Inc. (Dublin) |
Vibativ |
Telavancin; antibiotic |
Staphylococcus aureus |
Vibativ showed its activity against S. aureus clinical isolates causing skin infections or pneumonia with concomitant bacteremia |
6/6/17 |
Viamet Pharmaceuticals Inc. (Research Triangle Park, N.C.) |
VT-1161 |
Oteseconazole |
Recurrent yeast infections |
It met the primary endpoint of a phase IIb trial, besting a placebo in all arms of the trial |
6/6/17 |
Vical Inc. (San Diego) |
VL-2397 |
Antifungal |
Invasive aspergillosis |
A phase I trial showed it to be safe and well-tolerated with favorable plasma pharmacokinetic profiles in healthy study participants |
6/6/17 |
Notes The date indicated refers to the BioWorld issue in which the news item can be found. For more information about individual companies and/or products, see Cortellis. |